JP2022506891A - Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物 - Google Patents

Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物 Download PDF

Info

Publication number
JP2022506891A
JP2022506891A JP2021525000A JP2021525000A JP2022506891A JP 2022506891 A JP2022506891 A JP 2022506891A JP 2021525000 A JP2021525000 A JP 2021525000A JP 2021525000 A JP2021525000 A JP 2021525000A JP 2022506891 A JP2022506891 A JP 2022506891A
Authority
JP
Japan
Prior art keywords
alkyl
compound according
aryl
hydroxy
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021525000A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020102098A5 (https=
JP2022506891A5 (https=
Inventor
ゴッシュ，ショミア
カッツ，ジェイソン
ロウシュ，ウィリアム
セイデル，ハンズ，マーティン
シェン，ドン－ミン
ヴェンカトラマン，シャンカー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2022506891A publication Critical patent/JP2022506891A/ja
Publication of JPWO2020102098A5 publication Critical patent/JPWO2020102098A5/ja
Publication of JP2022506891A5 publication Critical patent/JP2022506891A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021525000A 2018-11-13 2019-11-11 Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物 Pending JP2022506891A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862760244P 2018-11-13 2018-11-13
US201862760195P 2018-11-13 2018-11-13
US201862760248P 2018-11-13 2018-11-13
US62/760,248 2018-11-13
US62/760,195 2018-11-13
US62/760,244 2018-11-13
PCT/US2019/060772 WO2020102098A1 (en) 2018-11-13 2019-11-11 Compounds and compositions for treating conditions associated with nlrp activity

Publications (3)

Publication Number Publication Date
JP2022506891A true JP2022506891A (ja) 2022-01-17
JPWO2020102098A5 JPWO2020102098A5 (https=) 2022-11-21
JP2022506891A5 JP2022506891A5 (https=) 2022-11-21

Family

ID=68916530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021525000A Pending JP2022506891A (ja) 2018-11-13 2019-11-11 Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物

Country Status (6)

Country Link
US (1) US12421223B2 (https=)
EP (1) EP3880673B1 (https=)
JP (1) JP2022506891A (https=)
CN (1) CN113015730A (https=)
ES (1) ES2974842T3 (https=)
WO (1) WO2020102098A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3649112A1 (en) * 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
ZA929699B (en) 1991-12-20 1994-06-14 Lilly Co Eli Sulfonimidamides
US5705398A (en) 1994-03-02 1998-01-06 The Scripps Research Institute Methods for identifying inhibitors of LPS-mediated LBP binding
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
CA2329065A1 (en) * 1998-05-05 1999-11-11 Francisco Xavier Talamas Pyrazole derivatives as p-38 map kinase inhibitors
KR101120857B1 (ko) 2003-06-26 2012-04-12 노파르티스 아게 5원의 헤테로사이클-기재 ｐ38 키나제 억제제
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
US8884006B2 (en) 2011-09-19 2014-11-11 University Of Puerto Rico Small-molecule inhibitors of Rac1 in metastatic breast cancer
TW201439066A (zh) 2012-11-30 2014-10-16 Kyowa Hakko Kirin Co Ltd 含氮雜環化合物
ITMI20131658A1 (it) 2013-10-08 2015-04-09 Getters Spa Combinazione di materiali per dispositivi di rilascio di mercurio e dispositivi contenenti detta combinazione di materiali
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
SI3259253T1 (sl) * 2015-02-16 2020-07-31 The University Of Queensland Sulfonilsečnine in sorodne spojine ter njihova uporaba
MX387515B (es) * 2015-10-29 2025-03-18 Merck Sharp & Dohme Llc Inhibidores de factor xia.
FR3046933B1 (fr) * 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
US11339136B2 (en) * 2016-04-18 2022-05-24 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
US11447460B2 (en) * 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
CA3021349A1 (en) 2016-04-19 2017-10-26 Innate Tumor Immunity, Inc. Nlrp3 modulators
JP6962941B2 (ja) 2016-06-14 2021-11-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Ａｐｊ受容体アゴニストとしての４−ヒドロキシ−３−スルホニルピリジン−２（１ｈ）−オン
EP3571187B1 (en) 2017-01-23 2023-11-22 Genentech, Inc. Chemical compounds as inhibitors of interleukin-1 activity
WO2018225018A1 (en) 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
ES2988798T3 (es) 2017-07-24 2024-11-21 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
EP3668840A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
CA3105521A1 (en) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Sulfonimidamide compounds as inhibitors of interleukin-1 activity
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
BR112021003665A2 (pt) 2018-09-13 2021-05-18 Bayer Aktiengesellschaft derivados de heterocicleno como agentes de controle de pragas
EP3911323A4 (en) 2019-01-18 2022-11-16 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
EP3986879B1 (en) 2019-06-21 2024-10-02 AC Immune SA Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators

Also Published As

Publication number Publication date
WO2020102098A1 (en) 2020-05-22
US12421223B2 (en) 2025-09-23
ES2974842T3 (es) 2024-07-01
EP3880673B1 (en) 2024-01-03
US20230025630A1 (en) 2023-01-26
CN113015730A (zh) 2021-06-22
EP3880673A1 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
JP7654767B2 (ja) Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
CN111094242B (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113166065B (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
JP2022505525A (ja) Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
JP2021529187A (ja) Ｎｌｒｐモジュレータ
JP2020537657A (ja) Ｎｌｒｐ活性に関連する病態を治療するためのスルホンアミド及びその組成物
JP2021529780A (ja) Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
US12134611B2 (en) Compounds and compositions for treating conditions associated with NLRP activity
JP2022507506A (ja) Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
JP2022518260A (ja) Ｎｌｒｐ活性に関連する状態を治療するためのスルホンイミドアミド化合物及び組成物
US20220227707A1 (en) Compounds and compositions for treating conditions associated with nlrp activity
US20220387397A1 (en) Compounds and compositions for treating conditions associated with nlrp activity
JP2021529186A (ja) Ｎｌｒｐ調節剤
JP2022507505A (ja) Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
JP2022506891A (ja) Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物
TWI914296B (zh) 用於治療與nlrp 活性相關的病症之化合物及組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240319